| Name | Title | Contact Details |
|---|
Spectranetics is dedicated to managing every lead and eradicating restenosis and amputation. We do this by helping physicians, patients, and hospitals maximize cardiovascular health. Our company is committed to inventing, selling, and supporting technology that enables success during the most challenging minimally invasive cardiovascular procedures. We provide expert physician training, including the only lead removal simulator in the industry, as well as extensive patient and physician education. The Company’s Lead Management (LM) division is dedicated to helping physicians safely manage every lead. We provide the expert tools, training and ongoing support – including the only available lead extraction simulator – that allow physicians precision, control and versatility while extracting leads, so they can focus more on the patient’s overall status while generating positive outcomes. The Vascular Intervention (VI) division is dedicated to helping physicians address the challenges of peripheral and coronary artery disease. We provide expert tools, training, ongoing support, and patient education so that you can help eradicate restenosis and amputation
BioAbility is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synteract, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthLeaders-InterStudy is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.